Pathogenesis of Castleman Disease
Castleman disease is fundamentally driven by dysregulated cytokine signaling, particularly interleukin-6 (IL-6), with distinct pathogenic mechanisms varying by subtype: HHV-8-associated MCD results from viral-induced cytokine production, while idiopathic MCD involves aberrant immune cell activation including peripheral helper T (Tph) cells and the JAK-STAT3 pathway 1, 2.
Core Pathogenic Mechanisms
Cytokine Dysregulation
IL-6 serves as the central mediator across most CD subtypes, causing:
- Systemic inflammatory symptoms
- Lymphoproliferation and lymphadenopathy
- Polyclonal hypergammaglobulinemia
- Vascular endothelial growth factor (VEGF)-mediated hypervascularization 3, 4
The IL-6-driven pathogenesis explains why only 30-60% of patients respond to IL-6 inhibitors—other pathways are simultaneously active 1.
Subtype-Specific Pathogenesis
HHV-8-Associated MCD:
- Viral products directly induce cytokine overproduction
- HHV-8 encodes a viral IL-6 homolog that activates signaling pathways
- Can progress to atypical lymphoproliferations and lymphoma (particularly PEL and DLBCL)
- Often co-infected with EBV, suggesting herpesvirus interplay in lymphomagenesis 5, 2
Idiopathic MCD (iMCD): Recent mechanistic insights reveal:
- Peripheral helper T (Tph) cell abnormalities are central to pathogenesis
- Tph cells produce excessive CXCL13, driving B-cell activation
- Activation of JAK-STAT3 signaling pathway perpetuates inflammation
- PI3K/Akt/mTOR pathway activation contributes to lymphoproliferation 1
The iMCD-TAFRO subtype demonstrates particularly aggressive pathophysiology with:
- Severe cytokine storm resembling hemophagocytic lymphohistiocytosis
- Resistance to IL-6 inhibitors
- mTORC1 hyperactivation, explaining responsiveness to mTOR inhibitors 6, 7
Cellular and Tissue Changes
Histopathologic features reflect the underlying pathogenesis 3:
- Atrophic or hyperplastic germinal centers
- Prominent follicular dendritic cell proliferation
- Marked hypervascularization (VEGF-mediated)
- Polyclonal lymphoproliferation
- Polytypic plasmacytosis
Clinical Implications of Pathogenesis
Critical Pitfall: The shared nomenclature between unicentric and multicentric CD is misleading—these are fundamentally different diseases with distinct pathogenic mechanisms and prognoses 2.
Therapeutic Targets Derived from Pathogenesis
The understanding of pathogenic pathways directly informs treatment selection 1, 6:
- IL-6 pathway: Siltuximab (anti-IL-6) or tocilizumab (anti-IL-6R) for iMCD-IPL
- B-cell pathway: Rituximab for HHV-8-MCD and refractory iMCD
- JAK-STAT3 pathway: JAK inhibitors under investigation for refractory cases
- mTOR pathway: Sirolimus/everolimus for iMCD-TAFRO and IL-6 inhibitor-refractory disease
- Tph-CXCL13-B cell axis: Emerging therapeutic target for refractory cases 1
HHV-8-MCD Specific Considerations
In HIV-associated cases, the pathogenesis involves 5:
- High HHV-8 viral loads driving cytokine production
- Elevated serum IL-6, IL-10, and C-reactive protein
- Risk of concurrent Kaposi sarcoma (shared HHV-8 etiology)
- Increased NHL incidence despite treatment
Important caveat: Even with undetectable HIV RNA, HHV-8-MCD can occur, requiring prompt intervention with rituximab to control viral-induced cytokine storm 5.
Unresolved Pathogenic Questions
Despite advances, significant gaps remain 2, 4:
- Why some patients develop unicentric versus multicentric disease
- Precise triggers initiating cytokine dysregulation in iMCD
- Why iMCD-TAFRO is resistant to IL-6 blockade while iMCD-IPL responds
- Role of genetic predisposition
The heterogeneous clinical presentations and varied responses to therapy reflect our incomplete understanding of the full pathogenic spectrum 7.